Talis Biomedical Q2 EPS $(8.27) Misses $(0.73) Estimate, Sales $581.00K Up From $572.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Talis Biomedical (NASDAQ:TLIS) reported Q2 losses of $(8.27) per share, missing the analyst consensus estimate of $(0.73) by 1032.88 percent. However, this is a 45.41 percent increase over losses of $(15.15) per share from the same period last year. The company reported $581.00 thousand in sales this quarter, a 1.57 percent increase YoY.
August 10, 2023 | 9:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Talis Biomedical's Q2 earnings missed estimates significantly, but showed improvement YoY. Sales also increased slightly YoY.
Talis Biomedical's Q2 earnings missed estimates by a large margin, which could negatively impact investor sentiment and the stock price. However, the YoY improvement in losses and slight increase in sales could provide some positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100